Primary Biliary Cholangitis: Promising Emerging Innovative Therapies and Their Impact on GLOBE Scores

Abstract Primary biliary cholangitis (PBC), previously referred to as primary biliary cirrhosis, is an autoimmune disorder leading to the destruction of intra-hepatic bile ducts. If untreated, progressive bile duct damage and cholestasis can lead to ductopenia and result in cirrhosis. Ursodiol, the first drug approved for PBC, has changed the natural history of this disease and improved patient outcomes. Subsequently, several new prediction models incorporating a response to ursodiol were developed. These include the GLOBE score, which was shown to predict long-term outcomes in patients with PBC. In 2016, obeticholic acid (OCA) became the second drug to be approved by the FDA, predominantly based on improvement in alkaline phosphatase (ALP) levels. This trial has subsequently influenced the design of clinical trials. Several drugs are currently being evaluated as therapeutic options for PBC, with improvement in ALP being a main endpoint. In this review, we will discuss the impact of new therapies on GLOBE scores in patients with PBC.

[1]  H. Yoshiji,et al.  Benefit of glucosyl Hesperidin in patients with primary biliary cholangitis: A multicenter, open-label, randomized control study , 2022, Medicine.

[2]  R. von Maltzahn,et al.  GLIMMER: A randomized Phase 2b dose-ranging trial of linerixibat in primary biliary cholangitis patients with pruritus. , 2022, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[3]  Changcun Guo,et al.  Efficacy and safety of fenofibrate addition therapy in patients with cirrhotic primary biliary cholangitis with incomplete response to ursodeoxycholic acid , 2022, Hepatology communications.

[4]  K. Kowdley,et al.  Application of the Latest Advances in Evidence-Based Medicine in Primary Biliary Cholangitis , 2022, The American journal of gastroenterology.

[5]  F. Nevens,et al.  Greater Transplant-free Survival in Patients Receiving Obeticholic Acid for Primary Biliary Cholangitis in a Clinical Trial Setting Compared to Real-World External Controls. , 2022, Gastroenterology.

[6]  C. Xi,et al.  Efficacy and safety of fenofibrate add-on therapy in patients with primary biliary cholangitis refractory to ursodeoxycholic acid: A retrospective study and updated meta-analysis , 2022, Frontiers in Pharmacology.

[7]  K. Kowdley,et al.  Farnesoid X receptor agonist tropifexor attenuates cholestasis in a randomised trial in patients with primary biliary cholangitis , 2022, JHEP reports : innovation in hepatology.

[8]  C. Mcwherter,et al.  323: SELADELPAR TREATMENT OF PATIENTS WITH PRIMARY BILIARY CHOLANGITIS (PBC) FOR 2 YEARS IMPROVES THE GLOBE PBC SCORE AND PREDICTS IMPROVED TRANSPLANT-FREE SURVIVAL , 2022, Gastroenterology.

[9]  Nannan Xu,et al.  Setanaxib (GKT137831) Ameliorates Doxorubicin-Induced Cardiotoxicity by Inhibiting the NOX1/NOX4/Reactive Oxygen Species/MAPK Pathway , 2022, Frontiers in Pharmacology.

[10]  Rohit Kohli,et al.  The Role of FGF19 and MALRD1 in Enterohepatic Bile Acid Signaling , 2022, Frontiers in Endocrinology.

[11]  C. Mcwherter,et al.  Seladelpar improved measures of pruritus, sleep, and fatigue and decreased serum bile acids in patients with primary biliary cholangitis , 2021, Liver international : official journal of the International Association for the Study of the Liver.

[12]  K. Gottlieb,et al.  Baricitinib and primary biliary cholangitis , 2021, Journal of translational autoimmunity.

[13]  Guangzhi Zhang,et al.  Combination antiretroviral therapy improves recurrent primary biliary cholangitis following liver transplantation , 2021, Liver international : official journal of the International Association for the Study of the Liver.

[14]  Ying Han,et al.  Fenofibrate improves GLOBE and UK-PBC scores and histological features in primary biliary cholangitis. , 2021, Minerva medica.

[15]  F. Carrat,et al.  Association of bezafibrate with transplant-free survival in patients with primary biliary cholangitis. , 2021, Journal of hepatology.

[16]  L. Muñoz-Espinosa,et al.  A Multicenter, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of Saroglitazar in Patients With Primary Biliary Cholangitis , 2021, Clinical and translational gastroenterology.

[17]  Results of a Phase 2, Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Efficacy of Saroglitazar Magnesium in Patients With Primary Biliary Cholangitis (EPICS). , 2021, Gastroenterology & hepatology.

[18]  G. Hirschfield.  ENHANCE: Safety and Efficacy of Seladelpar in Patients With Primary Biliary Cholangitis-A Phase 3, International, Randomized, Placebo-Controlled Study. , 2021, Gastroenterology & hepatology.

[19]  D. Magrez,et al.  A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA. , 2021, Journal of hepatology.

[20]  N. Shen,et al.  Fibrates for the treatment of pruritus in primary biliary cholangitis: a systematic review and meta-analysis. , 2021, Annals of palliative medicine.

[21]  A. Tanaka.  Current understanding of primary biliary cholangitis , 2020, Clinical and molecular hepatology.

[22]  J. Jia,et al.  Regional variation and temporal trend of primary biliary cholangitis epidemiology: A systematic review and meta‐analysis , 2020, Journal of gastroenterology and hepatology.

[23]  A. Floreani,et al.  Obeticholic acid is associated with improvements in AST-to-platelet ratio index and GLOBE score in patients with primary biliary cholangitis , 2020, JHEP reports : innovation in hepatology.

[24]  J. Trotter,et al.  Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis. , 2020, Gastroenterology.

[25]  M. Avila,et al.  S-adenosyl-L-methionine (SAMe) halts the autoimmune response in patients with primary biliary cholangitis (PBC) via antioxidant and S-glutathionylation processes in cholangiocytes. , 2020, Biochimica et biophysica acta. Molecular basis of disease.

[26]  P. Kamath,et al.  Liver Injury in Patients With Cholestatic Liver Disease Treated With Obeticholic Acid , 2020, Hepatology.

[27]  V. Wong,et al.  Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial , 2020, Hepatology.

[28]  J. Drenth,et al.  Elafibranor: a potential drug for the treatment of nonalcoholic steatohepatitis (NASH) , 2020, Expert opinion on investigational drugs.

[29]  M. Wagner,et al.  Drug Therapies for Chronic Cholestatic Liver Diseases. , 2020, Annual review of pharmacology and toxicology.

[30]  B. Neuschwander‐Tetri,et al.  Impact of Obeticholic Acid on the Lipoprotein Profile in Patients with Nonalcoholic Steatohepatitis. , 2020, Journal of hepatology.

[31]  H. Yoshiji,et al.  Bezafibrate Improves GLOBE and UK‐PBC Scores and Long‐Term Outcomes in Patients With Primary Biliary Cholangitis , 2019, Hepatology.

[32]  A. Quaas,et al.  Sex differences in clinical presentation and prognosis in patients with primary biliary cholangitis , 2019, Scandinavian journal of gastroenterology.

[33]  F. Nevens,et al.  Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis. , 2019, Journal of hepatology.

[34]  M. Gershwin,et al.  Therapeutic trials of biologics in primary biliary cholangitis: An open label study of abatacept and review of the literature. , 2019, Journal of autoimmunity.

[35]  K. Kowdley,et al.  The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS‐9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis , 2019, Hepatology.

[36]  M. Karsdal,et al.  Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: A multicenter, randomized, double-blind, placebo-controlled phase II trial. , 2019, Journal of hepatology.

[37]  G. Hirschfield,et al.  A Practical Review of Primary Biliary Cholangitis for the Gastroenterologist. , 2019, Gastroenterology & hepatology.

[38]  S. Medendorp,et al.  A Randomized, Controlled, Phase 2 Study of Maralixibat in the Treatment of Itching Associated With Primary Biliary Cholangitis , 2019, Hepatology communications.

[39]  J. Boyer,et al.  Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases , 2018, Hepatology.

[40]  Y. Kim,et al.  Prognostic Value of Biochemical Response Models for Primary Biliary Cholangitis and the Additional Role of the Neutrophil-to-Lymphocyte Ratio , 2018, Gut and liver.

[41]  M. Krawczyk,et al.  Effect of S-adenosyl-L-methionine on liver biochemistry and quality of life in patients with primary biliary cholangitis treated with ursodeoxycholic acid. A prospective, open label pilot study. , 2018, Journal of gastrointestinal and liver diseases : JGLD.

[42]  J. Jia,et al.  Efficacy and safety of fenofibrate add-on therapy for patients with primary biliary cholangitis and a suboptimal response to UDCA. , 2018, Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva.

[43]  A. Parés.  Primary biliary cholangitis. , 2018, Medicina clinica.

[44]  B. Leggett,et al.  NGM282 for Treatment of Patients With Primary Biliary Cholangitis: A Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Trial , 2018, Hepatology communications.

[45]  A. Goel,et al.  Natural History of Primary Biliary Cholangitis in the Ursodeoxycholic Acid Era: Role of Scoring Systems. , 2018, Clinics in liver disease.

[46]  V. de Lédinghen,et al.  A Placebo‐Controlled Trial of Bezafibrate in Primary Biliary Cholangitis , 2018, The New England journal of medicine.

[47]  M. Carbone,et al.  Risk stratification and prognostic modelling in primary biliary cholangitis. , 2018, Best practice & research. Clinical gastroenterology.

[48]  R. Chapman,et al.  NI‐0801, an anti‐chemokine (C‐X‐C motif) ligand 10 antibody, in patients with primary biliary cholangitis and an incomplete response to ursodeoxycholic acid , 2018, Hepatology communications.

[49]  Yasunori Sato,et al.  An impaired biliary bicarbonate umbrella may be involved in dysregulated autophagy in primary biliary cholangitis , 2018, Laboratory Investigation.

[50]  D. Aschenbrenner.  Excessive Dosing of Obeticholic Acid May Increase Risk of Liver Damage. , 2018, The American journal of nursing.

[51]  R. Chapman,et al.  A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis , 2018, Hepatology.

[52]  W. Wahli,et al.  Dual PPARα/γ agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models , 2017, Liver international : official journal of the International Association for the Study of the Liver.

[53]  Robert L. Martin,et al.  Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study. , 2017, The lancet. Gastroenterology & hepatology.

[54]  Xiaoli Fan,et al.  Underestimated Male Prevalence of Primary Biliary Cholangitis in China: Results of a 16-yr cohort study involving 769 patients , 2017, Scientific Reports.

[55]  G. Hirschfield,et al.  EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. , 2017, Journal of hepatology.

[56]  S. Kersten,et al.  The role and regulation of the peroxisome proliferator activated receptor alpha in human liver. , 2017, Biochimie.

[57]  Ying-Qiu Huang.  Recent advances in the diagnosis and treatment of primary biliary cholangitis , 2016, World journal of hepatology.

[58]  J. Reguła,et al.  A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis. , 2016, The New England journal of medicine.

[59]  A. Khanna,et al.  Long-Term Fenofibrate Treatment in Primary Biliary Cholangitis Improves Biochemistry but Not the UK-PBC Risk Score , 2016, Digestive Diseases and Sciences.

[60]  K. Lindor,et al.  Ustekinumab for patients with primary biliary cholangitis who have an inadequate response to ursodeoxycholic acid: A proof‐of‐concept study , 2016, Hepatology.

[61]  C. Bowlus,et al.  Management of symptom complexes in primary biliary cholangitis , 2016, Current opinion in gastroenterology.

[62]  C. Paulusma,et al.  Soluble Adenylyl Cyclase Regulates Bile Salt‐Induced Apoptosis in Human Cholangiocytes , 2016, Hepatology.

[63]  D. Brenner,et al.  The Role of NADPH Oxidases (NOXs) in Liver Fibrosis and the Activation of Myofibroblasts , 2016, Front. Physiol..

[64]  A. Burroughs,et al.  University of Birmingham Development and Validation of a Scoring System to Predict Outcomes of Patients With Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid Therapy , 2022 .

[65]  David C. Jones,et al.  Changing nomenclature for PBC: from ‘cirrhosis’ to ‘cholangitis’ , 2015, Gut.

[66]  B. Neuschwander‐Tetri.  Targeting the FXR nuclear receptor to treat liver disease. , 2015, Gastroenterology.

[67]  M. Yamada,et al.  A Prospective Randomized Controlled Study of Long-Term Combination Therapy Using Ursodeoxycholic Acid and Bezafibrate in Patients With Primary Biliary Cirrhosis and Dyslipidemia , 2015, The American Journal of Gastroenterology.

[68]  A. Burroughs,et al.  Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study. , 2014, Gastroenterology.

[69]  Q. Han,et al.  Allogeneic bone marrow mesenchymal stem cell transplantation in patients with UDCA-resistant primary biliary cirrhosis. , 2014, Stem cells and development.

[70]  S. Lens,et al.  Bezafibrate normalizes alkaline phosphatase in primary biliary cirrhosis patients with incomplete response to ursodeoxycholic acid , 2014, Liver international : official journal of the International Association for the Study of the Liver.

[71]  Ying Sun,et al.  A pilot study of umbilical cord‐derived mesenchymal stem cell transfusion in patients with primary biliary cirrhosis , 2013, Journal of gastroenterology and hepatology.

[72]  A. Burroughs,et al.  Impact of primary biliary cirrhosis on perceived quality of life: The UK‐PBC national study , 2013, Hepatology.

[73]  M. Swain,et al.  B-Cell Depletion With Rituximab in Patients With Primary Biliary Cirrhosis Refractory to Ursodeoxycholic Acid , 2013, The American Journal of Gastroenterology.

[74]  Y. Nakanuma,et al.  PPARγ ligand attenuates portal inflammation in the MRL-lpr mouse: a new strategy to restrain cholangiopathy in primary biliary cirrhosis , 2013, Medical Molecular Morphology.

[75]  J. Gustafsson,et al.  Liver X receptor β and peroxisome proliferator‐activated receptor δ regulate cholesterol transport in murine cholangiocytes , 2012, Hepatology.

[76]  K. Lindor,et al.  Biochemical and immunologic effects of rituximab in patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid , 2012, Hepatology.

[77]  J. Prieto,et al.  Ursodeoxycholic Acid Is Conjugated with Taurine to Promote Secretin-Stimulated Biliary Hydrocholeresis in the Normal Rat , 2011, PloS one.

[78]  O. Chazouilleres,et al.  Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome. , 2011, Journal of hepatology.

[79]  S. Kliewer,et al.  FGF15/19 regulates hepatic glucose metabolism by inhibiting the CREB-PGC-1α pathway. , 2011, Cell metabolism.

[80]  U. Beuers,et al.  Pathophysiology and current management of pruritus in liver disease. , 2011, Clinics and research in hepatology and gastroenterology.

[81]  K. Lindor,et al.  Pilot study: fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid , 2011, Alimentary pharmacology & therapeutics.

[82]  T. Arenovich,et al.  Baseline Ductopenia and Treatment Response Predict Long-Term Histological Progression in Primary Biliary Cirrhosis , 2010, The American Journal of Gastroenterology.

[83]  G. Gores,et al.  Biliary apotopes and anti-mitochondrial antibodies activate innate immune responses in primary biliary cirrhosis. , 2010, Hepatology.

[84]  A. Chawla.  Control of macrophage activation and function by PPARs. , 2010, Circulation research.

[85]  M. Elisaf,et al.  Fenofibrate in Primary Biliary Cirrhosis: A Pilot Study , 2010, The open cardiovascular medicine journal.

[86]  B. Lemon,et al.  FGF19-induced Hepatocyte Proliferation Is Mediated through FGFR4 Activation , 2009, The Journal of Biological Chemistry.

[87]  Lawrence Steinman,et al.  PPAR-δ senses and orchestrates clearance of apoptotic cells to promote tolerance , 2009, Nature Medicine.

[88]  D. Vergani,et al.  New ELISA for detecting primary biliary cirrhosis-specific antimitochondrial antibodies. , 2009, Clinical chemistry.

[89]  K. V. van Erpecum,et al.  Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid. , 2009, Gastroenterology.

[90]  I. Fabregat,et al.  Upregulation of the NADPH oxidase NOX4 by TGF-beta in hepatocytes is required for its pro-apoptotic activity. , 2008, Journal of hepatology.

[91]  I. Mackay,et al.  CD4 T-cell autoreactivity to the mitochondrial autoantigen PDC-E2 in AMA-negative primary biliary cirrhosis. , 2008, Journal of autoimmunity.

[92]  Y. Chrétien,et al.  Biochemical response to ursodeoxycholic acid and long‐term prognosis in primary biliary cirrhosis , 2008, Hepatology.

[93]  I. Mackay,et al.  Autoimmune liver serology: current diagnostic and clinical challenges. , 2008, World journal of gastroenterology.

[94]  S. Kaneko,et al.  The efficacy of ursodeoxycholic acid and bezafibrate combination therapy for primary biliary cirrhosis: A prospective, multicenter study , 2008, Hepatology research : the official journal of the Japan Society of Hepatology.

[95]  Liang Zhu,et al.  Long-Term Effects of Mid-Dose Ursodeoxycholic Acid in Primary Biliary Cirrhosis: A Meta-analysis of Randomized Controlled Trials , 2006, The American Journal of Gastroenterology.

[96]  Shinichiro Yamamoto,et al.  Long-term effect of bezafibrate on parameters of hepatic fibrosis in primary biliary cirrhosis , 2006, Journal of Gastroenterology.

[97]  J. Prieto,et al.  Bicarbonate-rich choleresis induced by secretin in normal rat is taurocholate-dependent and involves AE2 anion exchanger. , 2006, Hepatology.

[98]  K. Tsuneyama,et al.  Liver‐targeted and peripheral blood alterations of regulatory T cells in primary biliary cirrhosis , 2006, Hepatology.

[99]  J. Rodés,et al.  Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid. , 2006, Gastroenterology.

[100]  K. Isse,et al.  Th1 cytokine–induced downregulation of PPARγ in human biliary cells relates to cholangitis in primary biliary cirrhosis , 2005, Hepatology.

[101]  J. Neuberger,et al.  Pilot Studies of Single and Combination Antiretroviral Therapy in Patients with Primary Biliary Cirrhosis , 2004, The American Journal of Gastroenterology.

[102]  J. Talwalkar,et al.  Natural history of pruritus in primary biliary cirrhosis. , 2003, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[103]  T. Sauerbruch,et al.  Pharmacokinetics and pharmacodynamic action of budesonide in early‐ and late‐stage primary biliary cirrhosis , 2003, Hepatology.

[104]  N. LaRusso,et al.  Cholangiocyte biology , 2003, Current opinion in gastroenterology.

[105]  U. Beuers,et al.  Ursodeoxycholic acid in cholestatic liver disease: Mechanisms of action and therapeutic use revisited , 2002, Hepatology.

[106]  T. Ueno,et al.  Fenofibrate treatment in patients with primary biliary cirrhosis , 2002, American Journal of Gastroenterology.

[107]  T. Willson,et al.  6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. , 2002, Journal of medicinal chemistry.

[108]  J. Neuberger,et al.  Defective regulation of cholangiocyte Cl−/HCO−3 and Na+/H+ exchanger activities in primary biliary cirrhosis , 2002, Hepatology.

[109]  G. Gores,et al.  Ursodeoxycholic acid 'mechanisms of action and clinical use in hepatobiliary disorders'. , 2001, Journal of hepatology.

[110]  T M Therneau,et al.  A model to predict survival in patients with end‐stage liver disease , 2001, Hepatology.

[111]  T M Therneau,et al.  Adaptation of the mayo primary biliary cirrhosis natural history model for application in liver transplant candidates , 2000, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[112]  S. Iwasaki.  Bezafibrate may have a beneficial effect in pre-cirrhotic primary biliary cirrhosis , 1999 .

[113]  T. Therneau,et al.  Utilization of the Mayo risk score in patients with primary biliary cirrhosis receiving ursodeoxycholic acid. , 1999, Liver.

[114]  M. Strazzabosco,et al.  Transport systems in cholangiocytes: their role in bile formation and cholestasis. , 1997, The Yale journal of biology and medicine.

[115]  J. Prieto,et al.  Decreased anion exchanger 2 immunoreactivity in the liver of patients with primary biliary cirrhosis , 1997, Hepatology.

[116]  P. Grambsch,et al.  Primary biliary cirrhosis: Prediction of short‐term survival based on repeated patient visits , 1994, Hepatology.

[117]  J. Medina,et al.  Immunohistochemical detection of chloride/bicarbonate anion exchangers in human liver , 1994, Hepatology.

[118]  D G Altman,et al.  Updating prognosis in primary biliary cirrhosis using a time-dependent Cox regression model. PBC1 and PBC2 trial groups. , 1993, Gastroenterology.

[119]  P. Grambsch,et al.  Prognosis in primary biliary cirrhosis: Model for decision making , 1989, Hepatology.

[120]  A. Ryrfeldt,et al.  Liver metabolism of budesonide in rat, mouse, and man. Comparative aspects. , 1987, Drug metabolism and disposition: the biological fate of chemicals.

[121]  D. Altman,et al.  Beneficial effect of azathioprine and prediction of prognosis in primary biliary cirrhosis. Final results of an international trial. , 1985, Gastroenterology.

[122]  J. Boyer,et al.  The prognostic importance of clinical and histologic features in asymptomatic and symptomatic primary biliary cirrhosis. , 1983, The New England journal of medicine.

[123]  L. Hellman,et al.  REDUCTION OF CHOLESTEROL AND LIPIDS IN MAN BY ETHYL P-CHLOROPHENOXYISOBUTYRATE. , 1963, Annals of internal medicine.

[124]  A. Parés,et al.  Effects of Bezafibrate on Outcome and Pruritus in Primary Biliary Cholangitis With Suboptimal Ursodeoxycholic Acid Response , 2018, The American Journal of Gastroenterology.

[125]  F. Nevens,et al.  Time-dependent factors associated with diminished transplant-free survival in patients with primary biliary cholangitis and an optimal response to ursodeoxycholic acid after one year of treatment , 2017 .

[126]  K. Tsuneyama,et al.  Primary Biliary Cholangitis: Its Pathological Characteristics and Immunopathological Mechanisms. , 2017, The journal of medical investigation : JMI.

[127]  F. Nevens,et al.  The GLOBE score identifies PBC patients at increased risk of liver transplantation or death in different age-categories over time , 2017 .

[128]  F. Nevens,et al.  The GLOBE score identifies PBC patients at increased risk of liver transplantation or death during follow-up , 2016 .

[129]  C. Selmi,et al.  Experimental evidence on the immunopathogenesis of primary biliary cirrhosis , 2010, Cellular and Molecular Immunology.

[130]  T. Kurihara,et al.  Investigation into the efficacy of bezafibrate against primary biliary cirrhosis, with histological references from cases receiving long term monotherapy , 2002, American Journal of Gastroenterology.

[131]  M. Kaplan,et al.  Identification of HLA-A2-restricted CD8(+) cytotoxic T cell responses in primary biliary cirrhosis: T cell activation is augmented by immune complexes cross-presented by dendritic cells. , 2002, The Journal of experimental medicine.

[132]  T. Kurihara,et al.  Bezafibrate in the treatment of primary biliary cirrhosis: comparison with ursodeoxycholic acid , 2000, American Journal of Gastroenterology.

[133]  T. Masaki,et al.  Combination therapy of bezafibrate and ursodeoxycholic acid in primary biliary cirrhosis: a preliminary study , 2000, American Journal of Gastroenterology.

[134]  M. Manns,et al.  Is there a serological difference between men and women with primary biliary cirrhosis? , 1999, American Journal of Gastroenterology.

[135]  A. Hofmann,et al.  Pharmacology of ursodeoxycholic acid, an enterohepatic drug. , 1994, Scandinavian journal of gastroenterology. Supplement.

[136]  J. Senior,et al.  Effect of long-term treatment with ursodiol on clinical and biochemical features and biliary bile acid metabolism in patients with primary biliary cirrhosis. , 1993, The American journal of gastroenterology.